Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 190

The DOI matches its Crossref record.

Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium

Open access
Salles, Gilles, de Jong, Daphne, Xie, Wanling, Rosenwald, Andreas, Chhanabhai, Mukesh, Gaulard, Philippe, Klapper, Wolfram, Calaminici, Maria, Sander, Birgitta, Thorns, Christoph, Campo, Elias, Molina, Thierry, Lee, Abigail, Pfreundschuh, Michael, Horning, Sandra, Lister, Andrew, Sehn, Laurie H., Raemaekers, John, Hagenbeek, Anton, Gascoyne, Randy D., Weller, Edie · 2011 · Blood

Abstract

The Lunenburg Lymphoma Biomarker Consortium (LLBC) evaluated the prognostic value of IHC biomarkers in a large series of patients with diffuse large B-cell lymphoma (DLBCL). Clinical data and tumor samples were retrieved from 12 studies from Europe and North America, with patients treated before or after the rituximab era. Using tissue microarrays from 1514 patients, IHC for BCL2, BCL6, CD5, CD10, MUM1, Ki67, and HLA-DR was performed and scored according to previously validated protocols. Optimal cut points predicting overall survival of patients treated in the rituximab era could only be determined for CD5 (P = .003) and Ki67 (P = .02), whereas such cut points for BCL2, BCL6, HLA-DR, and MUM1 could only be defined in patients not receiving rituximab. A prognostic model for patients treated in the rituximab era identified 4 risk groups using BCL2, Ki67, and International Prognostic Index (IPI) with improved discrimination of low-risk patients. Newly recognized correlations between specific biomarkers and IPI highlight the importance of carefully controlling for clinical and biologic factors in prognostic models. These data demonstrate that the IPI remains the best available index in patients with DLBCL treated with rituximab and chemotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2011-04-345256

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 190

Metadata

Authors
Salles, G., de Jong, D., Xie, W., Rosenwald, A., Chhanabhai, M., Gaulard, P., Klapper, W., Calaminici, M., Sander, B., Thorns, C., Campo, E., Molina, T., Lee, A., Pfreundschuh, M., Horning, S., Lister, A., Sehn, L. H., Raemaekers, J., Hagenbeek, A., Gascoyne, R. D., & Weller, E.
Venue
Blood
Published
2011-06-30
Volume
117
Issue
26
Pages
7070-7078
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2142814377
Cited by
190
References
0
FWCI
14.60
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. https://app.cochat.ai/papers/10.1182/blood-2011-04-345256
The paper
Salles, G., de Jong, D., Xie, W., Rosenwald, A., Chhanabhai, M., Gaulard, P., Klapper, W., Calaminici, M., Sander, B., Thorns, C., Campo, E., Molina, T., Lee, A., Pfreundschuh, M., Horning, S., Lister, A., Sehn, L. H., Raemaekers, J., Hagenbeek, A., . . . Weller, E. (2011). Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood. https://doi.org/10.1182/blood-2011-04-345256

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.